Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Silo Pharma announced progress on two strategic fronts: its QwikAgents AI subsidiary is preparing for commercial launch within 60-90 days to generate initial revenue in the enterprise AI market, while its lead PTSD therapeutic candidate SPC-15 advances through regulatory milestones including completion of a drug-device robustness study and preparation for an FDA Type C meeting. The company recently raised capital through a private placement to support these initiatives.